 Heat Biologics NASDAQ: HTBX, a prerevenue biotech, is off to a strong start today. Specifically, Heat announced that its COVID-19 vaccine candidate exhibited compelling evidence of immunogenicity the ability to provoke a bodys immune response in a preclinical animal study. While Heat is well behind the leaders in the race to develop a COVID-19 vaccine, these positive preclinical data could open the door for a lucrative collaboration with a big-name pharma or perhaps a sizable government grant. 